Fundraising FoxFrazier Life Sciences — 2016 Investments
6 investments dated 2016 · listed companies and verified rows first · show all
Alcresta Therapeutics develops enzyme-based therapeutic products to address nutritional care for enterally fed patients living with rare diseases.
BiotechHealthtechMedical DevicesMassachusetts, US
Daniel Orlando(Chief Executive Officer)inTasos Konidaris(Executive Officer)inMartin Paz(Executive Officer)inRobert Gallotto(Executive Officer)inDaniel Tasse(Executive Officer, Director)inWilliam Scheinler(Executive Officer)in
Board seatJames N. Topper· per SEC Form D
Co-investorsHealthQuest CapitalBessemer Venture PartnersThird Rock Ventures
BiotechEvanston, US
Joseph R. Moskal(Chief Scientific Officer)Torsten M. Madsen(Chief Marketing Officer)Ashish Khanna(Secretary & Chief Business Officer)Norbert G. Riedel(Chief Executive Officer)
BoardLiam Ratcliffe(Director)Terry P. Gould(Director)
Board seatJames N. Topper· per SEC Form D
Co-investorsBain Capital Life SciencesLatterell Venture PartnersLongitude CapitalOUP (Osage University Partners)Agent CapitalBain Capital+3 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Center for Orthopedic & Research ExcellenceMOD Super Fast Pizza HoldingsOutpost MedicineSG Pharmaceuticals
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.